Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Correlation between Duration of Concomitant Exposure to Acid Reduction Agents and Remission Rates in Newly Diagnosed CML Patients on TKI's

Adrian Kilcyone, Pierantonio Russo, Charlotta Liljebris, Ramaa Nathan, Carlton Anderson, Michael Sicilia, Alex Moore, Sudarshan Prasad, Per Andersson

Blood (2024) 144 (Supplement 1): 6606.

https://doi.org/10.1182/blood-2024-209909

Published: 2024

Journal Articles

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

Gunnar Larfors, Hans Lennernäs, Charlotta Liljebris, Magnus Brisander, Gérald Jesson, Per Andersson, Leif Stenke

Blood (2022) 140 (Supplement 1): 6769–6770.

https://doi.org/10.1182/blood-2022-156487

Published: 2022

Journal Articles

XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use

Hans Lennernäs, Charlotta Liljebris, Magnus Brisander, Gérald Jesson, Per Andersson, Gunnar Larfors, Leif Stenke

Blood (2022) 140 (Supplement 1): 9652–9653.

https://doi.org/10.1182/blood-2022-169884

Published: 2022

Journal Articles

Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer

Nina Mohell, PhD, Charlotta Liljebris, PhD, Jessica Alfredsson, PhD, Ylva Lindman, MSc, Maria Uustalu, MSc, Thomas Uhlin, BSc, Mats R.H. Linderholm, MD, PhD, Klas G. Wiman, MD, PhD

Blood (2010) 116 (21): 1806.

https://doi.org/10.1182/blood.V116.21.1806.1806

Published: 2010

Journal Articles

Further Preclinical Studies with APR-246, a Novel Anticancer Compound Currently in Clinical Trials for Hematological Malignancies and Prostate Cancer.

Nina Mohell, PhD, Charlotta Liljebris, PhD, Jessica Alfredsson, PhD, Ylva Lindman, MSc, Maria Uustalu, MSc, Klas G Wiman, PhD, MD, Thomas Uhlin, BSc

Blood (2009) 114 (22): 3773.

https://doi.org/10.1182/blood.V114.22.3773.3773

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Correlation between Duration of Concomitant Exposure to Acid Reduction Agents and Remission Rates in Newly Diagnosed CML Patients on TKI's

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use

Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer

Further Preclinical Studies with APR-246, a Novel Anticancer Compound Currently in Clinical Trials for Hematological Malignancies and Prostate Cancer.

Email alerts

ASH Publications

American Society of Hematology

Update search

Correlation between Duration of Concomitant Exposure to Acid Reduction Agents and Remission Rates in Newly Diagnosed CML Patients on TKI's

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use

Preclinical Efficacy and Toxicology Studies of APR-246, a Novel Anticancer Compound Currently In Clinical Trials for Refractory Hematological Malignancies and Prostate Cancer

Further Preclinical Studies with APR-246, a Novel Anticancer Compound Currently in Clinical Trials for Hematological Malignancies and Prostate Cancer.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only